Huanjia Zhang

The UK-based nanopore sequencing company's 2022 revenues were £198.6 million ($243.3 million), including £146.8 million from life science research tools.

Funded by the Lustgarten Foundation, the researchers plan to analyze 400-plus pancreatic cancer samples to study the genetic changes linked to the disease.

Doggybone DNA, from UK CDMO Touchlight, is an enzymatically amplified DNA vector with a linear, double-stranded, and covalently closed structure.

The Watertown, Massachusetts-based company said its single-cell partitioning method is a flexible and scalable alternative to microfluidics-based scRNA-seq.

Developed at the University of Cambridge, Chem-map allows in situ mapping of small molecules that bind to cellular genomic DNA or chromatin-associated proteins.

MATQ-Drop is a high-throughput transcriptome profiling tool that allows scientists to study individual synapses at the subcellular level.

A new massively parallel reporter assay enables researchers to study cis-regulatory sequences across multiple cell types at the single-cell level.

The Seattle-based immune sequencing firm reported a 46 percent increase in fourth quarter revenues, about equally split between its MRD and immune medicine businesses.

The Chinese next-generation sequencing instrumentation firm expects its net profit attributable to shareholders to be at least RMB 1.94 billion ($284.2 million).

The project, presented last week at the annual AGBT meeting, hopes to establish a genomic research governance framework and to build a variant library with Indigenous communities.